We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for Sipavibart (AstraZeneca Pty Ltd)
Active ingredients
Sipavibart
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
AZD3152 is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who are immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments.
Therapeutic area
Infectious diseases